US OptionsDetailed Quotes

CGEN241220C2500

Watchlist

0.05
0.000.00%

15min DelayClose Dec 2 16:00 ET

0.05High0.04Low

Compugen Stock Discussion

Jaguar8

Nov 27 06:03

NEWS

$Compugen (CGEN.US)$
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Compugen (NASDAQ: CGEN) has been granted a new U.S. patent (No. 12152084) covering the triple combination use of its COM902 anti-TIGIT antibody with anti-PD-1 and anti-PVRIG antibodies for cancer treatment.
The patent strengthens Compugen's IP portfolio and protects the use of COM902, a reduc...

Tsukasa0_0

May 30 22:01

About to Receive Milestone Payment

$Compugen (CGEN.US)$ 🤩
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

Moomoo AI

Mar 8 05:18

The market anticipates a decline in future revenue, possibly explaining the suppressed P/S. This weak revenue outlook could continue to pressure shares, making it hard to maintain current prices. Shareholders accept the low P/S, expecting future revenue may not bring pleasant surprises.

Compugen Ltd. (NASDAQ:CGEN) Held Back By Insufficient Growth Even After Shares Climb 26%

Bigmoney Dreamer

Mar 5 12:00

$Compugen (CGEN.US)$ fk entered very early! now no option to hold at lesast 2 week or more !

Bigmoney Dreamer

Mar 4 18:23

$Compugen (CGEN.US)$ 👀looks good i n game 🎲

Moomoo AI

Feb 15 06:06

Michelle Mahler's appointment as Chief Medical Officer is a positive step for Compugen, thanks to her vast clinical development experience. Her leadership in the COM503 Phase 1 study and future role in advancing COM701, COM902, and COM503 are anticipated to significantly boost the company's clinical development strategy.